A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial, according to ...

The failure of Pfizer Inc.’s obesity pill, its highest profile experimental drug, raises the odds that the drugmaker will ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.      The drugmaker said on ...

Pfizer has stopped the development of its promising obesity pill, danuglipron, following a safety incident during clinical ...

Novo Nordisk said on Monday it has become aware of several hundred units of counterfeit versions of its diabetes drug Ozempic ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer has made competing in the obesity market central to its post-Covid comeback plan. As demand for coronavirus vaccines ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

India's anti-obesity drug market shows significant growth. It has increased fourfold in five years. Lifestyle diseases and ...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025.

(Bloomberg) -- As Novo Nordisk A/S shares head for their worst ... disappointing data from a mid-stage trial for its weight-loss pill monlunabant last year, followed by results for a separate ...